Computed Tomographic Angiography in Acute Pulmonary Embolism

2008 ◽  
Vol 32 (3) ◽  
pp. 438-443 ◽  
Author(s):  
Ehab M. Kamel ◽  
Sabine Schmidt ◽  
Francesco Doenz ◽  
Ghazal Adler-Etechami ◽  
Pierre Schnyder ◽  
...  
2009 ◽  
Vol 33 (6) ◽  
pp. 961-966 ◽  
Author(s):  
Diana Litmanovich ◽  
Phillip M. Boiselle ◽  
Alexander A. Bankier ◽  
Milliam L. Kataoka ◽  
Oleg Pianykh ◽  
...  

2007 ◽  
Vol 82 (5) ◽  
pp. 556-560 ◽  
Author(s):  
David A. Froehling ◽  
Paul R. Daniels ◽  
Stephen J. Swensen ◽  
John A. Heit ◽  
Jayawant N. Mandrekar ◽  
...  

2006 ◽  
Vol 130 (9) ◽  
pp. 1326-1329
Author(s):  
Stacy E. F. Melanson ◽  
Michael Laposata ◽  
Carlos A. Camargo, Jr ◽  
Annabel A. Chen ◽  
Roderick Tung ◽  
...  

Abstract Context.—D-dimer concentration can be used to exclude a diagnosis of acute pulmonary embolism. However, clinicians frequently order unnecessary supplemental testing in patients with low concentrations of D-dimer. Elevations in natriuretic peptides have also been described in the setting of pulmonary embolism. Objective.—We investigated the integrative role of D-dimer with amino-terminal pro-B-type natriuretic peptide for the evaluation of patients with and without acute pulmonary embolism. Design.—Patients were selected for analysis from a previous study in which levels of D-dimer and amino-terminal pro-B-type natriuretic peptide were measured. The presence of pulmonary embolism was determined by computed tomographic angiography. Results.—The median levels of D-dimer were significantly higher in patients with acute pulmonary embolism. Similarly, the median levels of amino-terminal pro-B-type natriuretic peptide were higher in patients with pulmonary embolism. Conclusions.—The Roche Tina-quant D-Dimer immunoturbidimetric assay provides a high negative predictive value and can be used to exclude acute pulmonary embolism in patients with dyspnea. Measurement of amino-terminal pro-B-type natriuretic peptide in addition to D-dimer improves specificity for acute pulmonary embolism without sacrificing negative predictive value. A combination of both markers may offer reassurance for excluding acute pulmonary embolism, and thus avoid redundant, expensive confirmatory tests.


2003 ◽  
Vol 54 (3) ◽  
pp. 472-477 ◽  
Author(s):  
John T. Anderson ◽  
Tina Jenq ◽  
Martin Bain ◽  
Robert Jacoby ◽  
Robert Osnis ◽  
...  

2018 ◽  
Vol 25 (5) ◽  
pp. 469-477 ◽  
Author(s):  
Michael D. Repplinger ◽  
Scott K. Nagle ◽  
John B. Harringa ◽  
Aimee T. Broman ◽  
Christopher R. Lindholm ◽  
...  

Neurosurgery ◽  
2011 ◽  
Vol 68 (5) ◽  
pp. E1497-E1500 ◽  
Author(s):  
Bryan A. Pukenas ◽  
Sudhakar R. Satti ◽  
Robert Bailey ◽  
John B. Weigele ◽  
Robert W. Hurst ◽  
...  

Abstract BACKGROUND AND IMPORTANCE: Endovascular management of dural arteriovenous fistulas (DAVFs) has become an accepted primary and often definitive therapy. We present the first documented case of Onyx pulmonary embolism after embolization of a low-flow DAVF. CLINICAL PRESENTATION: A 63-year-old man presented with subarachnoid hemorrhage secondary to a DAVF. Computed tomographic angiography, magnetic resonance imaging, and initial conventional angiogram were negative. A repeat angiogram demonstrated a DAVF, which was cured with Onyx embolization. A routine chest computed tomography after intervention revealed an asymptomatic Onyx embolization cast in a subsegmental pulmonary artery. CONCLUSION: Endovascular treatment options include transarterial embolization with microcoils, polyvinyl alcohol particles, n-butyl-2cyanoacrylate, and Onyx (ev3 Neurovascular, Irvine, California). Complications associated with the use of Onyx are low but include embolizate pulmonary embolism. Patients often remain asymptomatic, but for symptomatic patients, conservative treatment options usually result in resolution of symptoms.


Sign in / Sign up

Export Citation Format

Share Document